Title:
FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/055542
Kind Code:
A8
Abstract:
Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Inventors:
STOVER DAVID (US)
BHARALI DHRUBA (US)
HAY BRUCE (US)
SAFEIE TAHMINEH (US)
BHARALI DHRUBA (US)
HAY BRUCE (US)
SAFEIE TAHMINEH (US)
Application Number:
PCT/US2021/010039
Publication Date:
December 21, 2023
Filing Date:
September 10, 2021
Export Citation:
Assignee:
NAMMI THERAPEUTICS INC (US)
International Classes:
C07J1/00; A61K31/704; A61K45/06; A61K47/54; A61K47/69; A61P35/00
Attorney, Agent or Firm:
POPP, Shane, M. (US)
Download PDF: